Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease

Abstract

The new MPFF 1000 mg dose regimen in once daily tablets was associated with a rapid and continuous reduction in leg pain throughout the 8-week treatment period.

Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence

“…There is also new clinical evidence confirming that MPFF treatment improves CVD symptoms in patients, and treatment with 1000 mg once per day may be sufficient. In a randomized, double-blind study in 174 CVD patients (C0s to C4) comparing MPFF treatment at 500 mg twice per day to 1000 mg once per day, patients in both treatment groups reported significant and similar reductions in leg pain assessed by visual analog scale (VAS) beginning after 2 weeks of treatment [12]. Pain continued to significantly improve in both treatment groups through weeks 4 and 8, with no significant differences between groups.…”

The Effectiveness and Safety of the Application of the Microionized Purified Flavonoid Fraction for the Treatment of the Patients Presenting with Concomitant Varicose Veins of the Pelvis and Lower Extremities

“…С позиций доказательной медицины МОФФ (детралекс, дафлон) имеет значительные преимущества перед существующими флеботропными препаратами, что объясняется ее фармакологическими качествами и способом изготовления. Многочисленными исследованиями доказано позитивное влияние МОФФ на клинические симптомы и отток крови из вен нижних конечностей при варикозной и посттромботической болезни [11][12][13]. Вместе с тем в литературе имеется крайне скудная информация о возможностях применения МОФФ в лечении ВБТ, синдрома тазового венозного полнокровия, вульварного варикоза, не говоря о ситуациях сочетанной варикозной трансформации внутритазовых, вульварных и поверхностных вен нижних конечностей.…”

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

“…RCTs 44,69,71,73,75,77,78,79,83 totaling 2222 patients showed a benefit of MPFF in improving sensory and functional symptoms of CVI, such as leg pain, paresthesia, and feeling of swelling. One observational study 81 and 2 RCTs 82 (including the unpublished Saveliev RCT) showed no significant differences in pain improvement with MPFF compared to no treatment with MPFF.…”